Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer

Patients with refractory metastatic triple-negative breast cancer (mTNBC) and symptomatic brain metastases have poor prognosis and are challenging to treat. The addition of an programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitor (pembrolizumab or atezolizumab) to first lin...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hongyuan Zhao, Weijie Ma, Ruben C. Fragoso, Griffith R. Harsh IV, Arya Ashok, Tianhong Li
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Multidisciplinary
Immune checkpoint inhibitor
Pdj amplification
Triple-negative breast cancer
Brain metastasis
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/b0207e3a22944f94890d61ef2e6ba3ed
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/b0207e3a22944f94890d61ef2e6ba3ed

Documents similaires